BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 32894794)

  • 21. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis.
    Orwoll ES; Scheele WH; Paul S; Adami S; Syversen U; Diez-Perez A; Kaufman JM; Clancy AD; Gaich GA
    J Bone Miner Res; 2003 Jan; 18(1):9-17. PubMed ID: 12510800
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterizing patients initiating abaloparatide, teriparatide, or denosumab in a real-world setting: a US linked claims and EMR database analysis.
    Imel EA; Starzyk K; Gliklich R; Weiss RJ; Wang Y; Williams SA
    Osteoporos Int; 2020 Dec; 31(12):2413-2424. PubMed ID: 32696118
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acting on black box warnings requires a GRADE evidence table and an implementation guide: the case of teriparatide.
    Elraiyah T; Gionfriddo MR; Murad MH
    J Clin Epidemiol; 2015 Jun; 68(6):698-702. PubMed ID: 25766055
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bone cancer incidence by morphological subtype: a global assessment.
    Valery PC; Laversanne M; Bray F
    Cancer Causes Control; 2015 Aug; 26(8):1127-39. PubMed ID: 26054913
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incidence Trends in the Diagnosis of Giant Cell Tumor of Bone in Sweden Since 1958.
    Rockberg J; Bach BA; Amelio J; Hernandez RK; Sobocki P; Engellau J; Bauer HC; Liede A
    J Bone Joint Surg Am; 2015 Nov; 97(21):1756-66. PubMed ID: 26537163
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Teriparatide: a review.
    Quattrocchi E; Kourlas H
    Clin Ther; 2004 Jun; 26(6):841-54. PubMed ID: 15262455
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Secondary malignant neoplasms among children, adolescents, and young adults with osteosarcoma.
    Lee JS; DuBois SG; Boscardin WJ; Wustrack RL; Goldsby RE
    Cancer; 2014 Dec; 120(24):3987-93. PubMed ID: 25116228
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Regional variation and challenges in estimating the incidence of giant cell tumor of bone.
    Liede A; Bach BA; Stryker S; Hernandez RK; Sobocki P; Bennett B; Wong SS
    J Bone Joint Surg Am; 2014 Dec; 96(23):1999-2007. PubMed ID: 25471915
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fluoride in drinking water and osteosarcoma incidence rates in the continental United States among children and adolescents.
    Levy M; Leclerc BS
    Cancer Epidemiol; 2012 Apr; 36(2):e83-8. PubMed ID: 22189446
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Age-specific fluoride exposure in drinking water and osteosarcoma (United States).
    Bassin EB; Wypij D; Davis RB; Mittleman MA
    Cancer Causes Control; 2006 May; 17(4):421-8. PubMed ID: 16596294
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Teriparatide treatment patterns in osteoporosis and subsequent fracture events: a US claims analysis.
    Bonafede MM; Shi N; Bower AG; Barron RL; Grauer A; Chandler DB
    Osteoporos Int; 2015 Mar; 26(3):1203-12. PubMed ID: 25567774
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Persistence with biologic therapies in the Medicare coverage gap.
    Tamariz L; Uribe CL; Luo J; Hanna JW; Ball DE; Krohn K; Meadows ES
    Am J Manag Care; 2011 Nov; 17(11):753-9. PubMed ID: 22084895
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comments on Initial experience with teriparatide in the United States.
    Harper KD; Krege JH; Marcus R; Mitlak BH
    Curr Med Res Opin; 2006 Oct; 22(10):1927. PubMed ID: 17022851
    [No Abstract]   [Full Text] [Related]  

  • 34. Association of Patient Enrollment in Medicare Part D With Outcomes After Acute Myocardial Infarction.
    Goyal A; de Lemos JA; Peng SA; Thomas L; Amsterdam EA; Hockenberry JM; Peterson ED; Wang TY
    Circ Cardiovasc Qual Outcomes; 2015 Nov; 8(6):567-75. PubMed ID: 26508667
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Incidence, epidemiology and treatment results of osteosarcoma in Finland - a nationwide population-based study.
    Sampo M; Koivikko M; Taskinen M; Kallio P; Kivioja A; Tarkkanen M; Böhling T
    Acta Oncol; 2011 Nov; 50(8):1206-14. PubMed ID: 22023116
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Initial experience with teriparatide in the United States.
    Gold DT; Pantos BS; Masica DN; Misurski DA; Marcus R
    Curr Med Res Opin; 2006 Apr; 22(4):703-8. PubMed ID: 16684431
    [TBL] [Abstract][Full Text] [Related]  

  • 37. International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons.
    Mirabello L; Troisi RJ; Savage SA
    Int J Cancer; 2009 Jul; 125(1):229-34. PubMed ID: 19330840
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Present at the beginning: a personal reminiscence on the history of teriparatide.
    Marcus R
    Osteoporos Int; 2011 Aug; 22(8):2241-8. PubMed ID: 21452026
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Endogenous gonadal hormone exposure and bone sarcoma risk.
    Cooley DM; Beranek BC; Schlittler DL; Glickman NW; Glickman LT; Waters DJ
    Cancer Epidemiol Biomarkers Prev; 2002 Nov; 11(11):1434-40. PubMed ID: 12433723
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bone sarcoma incidence in the Netherlands.
    Goedhart LM; Ho VKY; Dijkstra PDS; Schreuder HWB; Schaap GR; Ploegmakers JJW; van der Geest ICM; van de Sande MAJ; Bramer JA; Suurmeijer AJH; Jutte PC
    Cancer Epidemiol; 2019 Jun; 60():31-38. PubMed ID: 30903831
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.